MODEL TO DETECT WARFARIN-DRUG INTERACTIONS IN MAN

被引：24

作者：

DUURSEMA, L ^{[1
]}

MULLER, FO ^{[1
]}

HUNDT, HKL ^{[1
]}

HEYNS, AD ^{[1
]}

MEYER, BH ^{[1
]}

LUUS, HG ^{[1
]}

机构：

[1] UNIV ORANGE FREE STATE,DEPT PHARMACOL,FARMOVS INST CLIN PHARMACOL & DRUG DEV,POB 339,BLOEMFONTEIN 9300,SOUTH AFRICA

来源：

DRUG INVESTIGATION | 1992年 / 4卷 / 05期

关键词：

D O I：

10.1007/BF03258417

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aim of this study was to develop and validate a safe and sensitive in vivo model for the detection of potential warfarin-drug interactions in man. A single 25mg dose of racemic warfarin was administered to 18 consenting healthy male volunteers on day 4 of a randomised 7-day multiple dose regimen with one of the following treatments: vitamin K1 (10mg once daily in the evening), cholestyramine (4g three times daily before meals), rifampicin (600mg once daily in the morning), cimetidine (400mg twice daily), aspirin (600mg twice daily) or placebo (1 lactose capsule once daily in the morning). A total of 17 blood samples were obtained at predetermined intervals from 0 to 96 hours after warfarin ingestion for determination of prothrombin time, clotting factors II, VII and X, and total plasma warfarin concentration. The interacting agents produced clearly discernible effects on warfarin dynamics: attenuated by cholestyramine and rifampicin, potentiated by aspirin and cimetidine, and practically abolished by vitamin K1. The area under the plasma warfarin concentration-time curve was decreased by the presence of aspirin, rifampicin and cholestyramine, and increased by cimetidine. The model described appears to satisfy the criteria for detecting a potential clinically significant in vivo warfarin-drug interaction in healthy volunteers; the mechanism of such an interaction may be subsequently investigated using other methodology.

引用

页码：395 / 402

页数：8

共 21 条

[11]

O'Reilly R.A., Levy G., Pharmacokinetic analysis of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man, Journal of Pharmaceutical Sciences, 59, pp. 1258-1261, (1970)

[12]

Peterson C.E., Kwaan H.C., Current concepts of warfarin therapy, Archives of Internal Medicine, 146, pp. 581-584, (1986)

[13]

Serlin M.J., Breckenridge N.M., Drug interactions with warfarin, Drugs, 25, pp. 610-620, (1983)

[14]

Silver B.A., Bell W.R., Cimetidine potentiation of the hypoprothrombinemic effect of warfarin, Annals of Internal Medicine, 90, pp. 348-349, (1979)

[15]

Stirling Y., Howarth D.J., Stockley R., Bland R., Towler C.M., Et al., Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulations, British Journal of Haematology, 51, pp. 37-46, (1982)

[16]

Toon S., Hopkins K.J., Garstang F.M., Aarons L., Sedman A., Et al., Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects, Clinical Pharmacology and Therapeutics, 42, pp. 33-41, (1987)

[17]

Toon S., Hopkins K.J., Garstang F.M., Diquet B., Gill T.S., Et al., The warfarin-cimetidine interaction: stereochemical considerations (corresp.), British Journal of Clinical Pharmacology, 21, pp. 245-246, (1986)

[18]

Toon S., Hopkins K.J., Garstang F.M., Rowland M., Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man, European Journal of Clinical Pharmacology, 32, pp. 165-172, (1987)

[19]

Toon S., Lawrence K.L., Gibaldi M., Trager W.F., O'Reilly R.A., Et al., The warfarin-sulfinpyrazone interaction: stereochemical considerations, Clinical Pharmacology and Therapeutics, 39, pp. 15-24, (1986)

[20]

Toon S., Trager W.F., Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone (corresp.), Journal of Pharmaceutical Sciences, 73, pp. 1671-1673, (1984)

← 1 2 3 →